American Regent Announces CEO Transition for 2021

American Regent, a Daiichi Sankyo Group company, announced Ken Keller, currently serving as the company's President and CEO, is transitioning to a new role as the Global Head of Oncology Business at Daiichi Sankyo, effective April 1, 2021. He will remain President and CEO of Daiichi Sankyo, Paul Diolosa, currently Senior Vice President of Operations, will succeed Keller as President and CEO of American Regent effective April 1, 2021.

The transition aligns with Daiichi Sankyo's commitment to becoming a global pharmaceutical innovator with a focus on oncology, and American Regent's ongoing strategy for applying groundbreaking thinking to respond to customer needs by developing and delivering complex, hard-to-manufacture injectables and essential medicines.

"Serving as President and CEO of American Regent for almost the past five years has been an honor and a privilege for me," said Ken Keller. "In that time, the company has met or exceeded financial targets, delivered on key initiatives setting the framework for continued growth, and invested in expanding and modernizing its U.S.-based facilities to meet demand well into the future. More than that, I have worked with some of the most dedicated, professional, and passionate employees I have met in my career. Under Paul's leadership," Keller continued, "American Regent is positioned to continue realizing its vision of delivering on its most promising opportunities with staff who truly care."

"American Regent has always been committed to transformation, and I am extremely proud of stepping up to lead an exceptional organization dedicated to expanding its leading position as a developer, U.S. manufacturer, and supplier of important injectable medications for people and animals. As we move forward, I commit to strengthening our mission and purpose, and to empowering employees to innovatively meet the demands of a challenging healthcare market. What we do matters in helping improve the lives of millions of people," Paul Diolosa said.

Keller, who stepped into the role as President and CEO of American Regent in 2016, has more than 30 years of experience in the pharmaceutical industry in general management, commercial, international, and joint venture leadership, as well as chief operating officer experience in several therapeutic areas including oncology, rheumatology, dermatology, and primary care. Prior to joining American Regent, Keller was the President and Chief Operating Officer at Spectrum Pharmaceuticals and before that spent 21 years at Amgen leading highly successful, high profile business units across the globe, including leading the company's United Kingdom and Ireland Affiliates.

Paul Diolosa joined American Regent (then Luitpold Pharmaceuticals) in 2008 as Director of Engineering. Paul's leadership in modernizing its manufacturing operations led to his promotion to Vice President of Manufacturing, a role he assumed in October 2011. Diolosa has managed hundreds of millions in investment dollars to develop and build state-of-the-art facilities, and upgraded practices, validations, procedures, and testing with a commitment to controls and quality. In April 2020, Diolosa was promoted to Senior Vice President of Operations, leading a team of over 600 employees. Prior to joining American Regent, he served as Director of Engineering at Altana Pharmaceuticals for 10 years.